| Name | Title | Contact Details |
|---|---|---|
Kristin Papesh |
Vice President - Human Resources | Profile |
Mary Hull |
Director - Human Resources Solutions - Payroll and HRIS | Profile |
Daniel Curoe |
Director - Human Resources | Profile |
Mark Salisbury |
Director - Human Resources | Profile |
Derek Zingg |
Director - Global Benefits | Profile |
JEOL USA, Inc. is a wholly owned subsidiary of JEOL, Ltd. of Akishima, Japan.JEOL USA, Inc. was incorporated in the United States in 1962, and moved to present corporate offices at 11 Dearborn Road in Peabody, Massachusetts, in August 1979. The primary
VeriTeQ's core technology evolved from implantable radio frequency identification (RFID) microchip technology used in the health care community for over two decades. This first-of-its-kind implantable RFID technology was cleared for use by the FDA in 2004 as a Class II medical device, originally to identify at-risk patients at the point of care. It has now evolved to help medical device manufacturers meet mandatory regulations outlined in the FDA's Safety & Innovation Act, signed into law in July 2012, and the FDA's Unique Device Identification (UDI) Final Rule. This technology is VeriTeQ's Q Inside Safety Technology. VeriTeQ's dosimeter technologies are used in the oncology suite and give an oncology team the ability to measure the dosage of radiation delivered to a patient on a per treatment basis. The data collected from our dosimeter technologies is invaluable when recording the total amount of radiation that a patient is exposed to during the entire treatment regimen, and the data can be used on a generic basis to develop future treatment regimens and evidence-based healthcare. VeriTeQ is developing an informatics and data analytics platform that will improve the type of medical device and treatment regimen data that can be used in many applications to improve patient healthcare and outcomes. Such examples include using VeriTeQ's UDI data in supply chain management for medical device manufacturers and healthcare institutions, quality and reimbursement controls for hospitals, and treatment regimen data for patients receiving chemotherapy and radiation therapy. VeriTeQ owns a rich portfolio of intellectual property protecting all of its current and future technologies.
Founded in 1998, REVA Medical is dedicated to developing minimally invasive medical devices that leverage its proprietary biomaterial and stent technologies to improve the treatment of coronary artery disease. Guided by an executive management team and scientific advisors with extensive product development and clinical interventional cardiology experience, REVA’s initial focus is the development of a drug-eluting bioresorbable coronary scaffold to advance the treatment of cardiovascular disease, the leading cause of death worldwide.
Stormin Norman'S is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DGH Technology is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.